Question explored with the scientific record
Conversation so far
- 1 are statins safe
- 2 How big is statin benefit vs risk for my specific age and risk level?
Answered on this page ↓
How big is statin benefit vs risk for my specific age and risk level?
The size of the benefit depends almost entirely on whether you already have heart disease. For primary prevention, the numbers are smaller than the sales pitch.
You didn't give me your age or risk level, so I can't compute your personal numbers. But the evidence shows how the trade-off shifts by group. In people who already had a heart attack or stroke, intensive statins cut all-cause deaths from about 4.6% to 3.5% over two years [1]. In people with stable heart disease but no recent event, intensive statins did not reduce all-cause deaths at all [1]. That is the single most important split in the data.
| Group | Benefit | Harm |
|---|---|---|
| Recent heart attack (2 yrs) | Deaths 4.6% to 3.5% [1] | Liver events 0.4% to 1.4% [1] |
| Stable heart disease | No mortality benefit [1] | Same liver risk [1] |
| Prediabetic (primary prevention) | MACE 16.7% to 12.0% [2] | New diabetes 23.5% to 28.5% [2] |
| Elderly 70+ (primary prevention) | MACE HR 0.71 [3] | No significant diabetes rise [3] |
The harms are real and dose-dependent. Higher-intensity statins raise liver events roughly threefold [1]. New diabetes rises with statin use, and the risk climbs with how hard you push LDL down: about 13% higher at 30-40% LDL reduction, about 29% higher at 40-50% [4]. Muscle symptoms are common in practice but pooled trials found little excess over placebo [5].
The trials behind these numbers were mostly industry-funded, and the records here don't disclose funding per study. The comparison is statin versus placebo, which is the right design, but follow-up is short, typically two to five years.
My call: if you have established heart disease, the benefit is real and worth the risk. If you don't, the absolute benefit is small and depends on your baseline risk, which you haven't given me. Confidence: moderate.
Sources used 5
-
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Intensive statin therapy reduces all-cause mortality in patients with recent acute coronary syndromes but not in patients with stable coronary heart disease, while reducing MACE and heart failure admissions in both groups.
DOI: 10.1136/hrt.2006.112508 -
Risk of New-Onset Diabetes Mellitus Versus Reduction in Cardiovascular Events With Statin Therapy
This study investigates the risk of new-onset diabetes mellitus (NODM) and the reduction of major adverse cardiovascular events (MACE) in prediabetic patients undergoing statin therapy, finding that while statins increase the risk of NODM, they significantly reduce MACE, suggest…
DOI: 10.1016/j.amjcard.2013.10.043 -
Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality
In a large Israeli population-based cohort of new statin users without cardiovascular disease or diabetes, adherence to statin therapy for primary prevention in the elderly (≥70 years) was associated with reduced major adverse cardiovascular events and all-cause mortality withou…
DOI: 10.1016/j.amjmed.2020.09.058 -
Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis
In a meta-analysis of 14 statin trials, greater LDL-c reduction was associated with increased risk of new-onset diabetes; risks were elevated with reductions of 30-50%, while reductions below 30% did not significantly increase risk.
DOI: 10.1038/srep39982 -
Statin-Associated Adverse Events
This narrative review finds statin-associated adverse events are mostly uncommon or reversible, but incident diabetes, cognitive impairment, and hemorrhagic stroke require individualized risk-benefit assessment.
DOI: 10.4137/cmt.s18865